Advancement of a tissue oxygenation measurement device and evaluation of galectin-3 as novel noninvasive prognostic biomarkers for monitoring VCA rejection

The General Hospital Corporation, doing business as Massachusetts General Hospital, was awarded a $302,801 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420).

The grant will support research from September 1, 2022 to August 31, 2025 to advance a tissue oxygenation measurement device and evaluate galectin-3 as novel noninvasive prognostic biomarkers for monitoring vascularized composite allotransplant rejection. The research aims to transform military and public health care by developing medical solutions applicable to battlefield trauma and investigating innovative diagnostic methods, in alignment with the program's goals of supporting basic, applied, and advanced biomedical research. The work will be performed in Boston, Massachusetts by Massachusetts General Hospital in partnership with its parent organization, Partners Healthcare System Incorporated.